OstPo

OstPo

$32.40
RV45

OstPo is a practitioner-only listed medicine formulated with selected traditional Chinese medicine ingredients, including Epimedium brevicornu, Dipsacus asper, Rehmannia glutinosa, Salvia miltiorrhiza and related botanical extracts. It is intended for qualified healthcare practitioners seeking traditional support for kidney-yang, kidney-yin, mild joint aches and pains, and healthy sexual function.

60 x 500 mg capsules | AUST L 200312

Each 500 mg capsule contains:

Anemarrhena asphodeloides whole plant dry extract 50 mg
Equivalent to dry whole plant 300 mg

Cullen corylifolium seed dry extract 42 mg
Equivalent to dry seed 252 mg

Dipsacus asper root dry extract 80 mg
Equivalent to dry root 480 mg

Epimedium brevicornu leaf dry extract 130 mg
Equivalent to dry leaf 780 mg
Containing icariin 78 mg

Pyrola decorata whole plant dry extract 88 mg
Equivalent to dry whole plant 528 mg

Rehmannia glutinosa root dry extract 50 mg
Equivalent to dry root 300 mg

Salvia miltiorrhiza root dry extract 60 mg
Equivalent to dry root 360 mg

Traditionally used in Chinese medicine to:

  • warm, nourish, strengthen, tonify and enrich kidney / kidney-yang
  • nourish, tonify and replenish kidney-yin
  • relieve mild joint aches and pains
  • maintain / support healthy sexual function

Directions

Take 2–4 capsules daily, or as directed by a qualified healthcare practitioner.

Dosage and duration should be determined by the treating healthcare practitioner based on individual assessment.

Label statement

If symptoms persist, talk to your health professional.

This section is provided for qualified healthcare practitioners as professional education. It summarises selected ingredient-level, pathway-level and traditional-use research relating to kidney-yang, kidney-yin, mild joint comfort, healthy sexual function and bone-health pathway research. It does not represent additional ARTG indications for OstPo.

OstPo is relevant to practitioners interested in traditional Chinese medicine kidney-yang and kidney-yin support, mild joint aches and pains, healthy sexual function, musculoskeletal pattern assessment, icariin research and botanical bone-health pathway research.

Epimedium brevicornu is the major ingredient in OstPo by quantity and provides icariin. Epimedium and icariin have been widely discussed in professional literature in relation to bone metabolism, osteoblast and osteoclast pathway research, musculoskeletal ageing and traditional kidney-tonifying use. Recent systematic review and meta-analysis literature has examined Epimedium and its active components in primary osteoporosis research settings, including bone mineral density outcomes. This information is provided for practitioner education only and should not be interpreted as a claim that OstPo treats osteoporosis or increases BMD.

Dipsacus asper is traditionally used in Chinese medicine in kidney-supporting and musculoskeletal contexts. Practitioner interest may include traditional use in bone and tendon support, musculoskeletal comfort, kidney-tonifying patterns and botanical constituent research.

Cullen corylifolium seed is a source of bakuchiol-related compounds and has been discussed in professional literature in relation to phytochemistry, biological activity and traditional use. Preclinical research has examined bakuchiol and related constituents in bone-loss models, supporting ingredient-level education around bone-health pathways. This does not represent an osteoporosis, fracture or bone-density indication for OstPo.

Rehmannia glutinosa, Anemarrhena asphodeloides, Pyrola decorata and Salvia miltiorrhiza are included as part of the broader traditional formula profile. Practitioner interest may include kidney-yin support, kidney-yang balance, mild joint comfort, Blood and musculoskeletal pattern assessment, oxidative stress pathways and traditional vitality support.

The combination of Epimedium, Dipsacus, Cullen corylifolium, Rehmannia, Pyrola and Salvia supports practitioner education around traditional kidney-yang / kidney-yin support, mild joint comfort, healthy sexual function and musculoskeletal pathway research. Broader research areas such as osteoporosis, fracture healing, BMD increase, bone loss prevention, osteoblast mineralisation and menopausal bone disease should remain professional background only and not be presented as product indications.

This information is provided for practitioner education only and does not represent additional ARTG indications for OstPo.

References available to registered practitioners on request.